Digicon

@if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif

@if (isset(session()->get('doctor')['vCentralCode']))

Logout

@endif

@csrf

@if (isset(session()->get('doctor')['vCentralCode']))

Back

@else

@endif

Patient {{ $iPatientNo }}

A retrospective, cross-sectional, observational survey study to analyse the role of Lacosamide as a first add-on in the treatment of partial onset seizures

Inclusion criteria:

Adult patients diagnosed with partial onset seizures & prescribed Lacosamide as a first add-on

DEMOGRAPHIC DATA

Initials*

Serial No.*

Age (yr) *

Gender *

Male Female

Name of clinic/hospital*

Date of data collection*

GENERAL EXAMINATION FINDINGS

Weight (kgs)*

DETAILS OF DIAGNOSIS

Number of seizures at baseline (In last 6 weeks) before initiating Lacosamide*

1-5 6-10 10-20 >20

Duration of Seizures*

Less than 6 months 6 months-1 year 1 -2 years Over 2 -5 years Over 5 years

Duration of taking Anti-epileptic drugs*

Less than 6 months 6 months-1 year 1 - 5 years Over 2 - 5 years Over 5 years

Comorbidities, if any

Yes No

Comorbidities, if Yes

Conditions	YES or NO	Year	Months
Anxiety
Depression
Migraine
Mention others if any

Name of Primary drug i.e drug started on initial diagnosis *

Daily dose of Primary drug (mg/day)*

Reason for adding 2nd Drug*

Inadequate response to the primary therapy Safety concern with the primary therapy Specify, if any other reason

Other Class of Drug given along with above therapy^#

Sr. No	Generic Name	Route & Dose	Duration
Voltage-gated sodium channels
Voltage-gated calcium channels (T-type)
GABAA receptors
SV2A inhibitor
α2δ subunit of calcium channels
AMPA receptor
Carbonic anhydratase inhibition
Mention others if any

^#Molecular targets of clinically used ASDs

Ref: Löscher W, Potschka H, Sisodiya SM, et al. Drug Resistance in Epilepsy: Clinical Impact, Potential Mechanisms, and New Innovative Treatment Options. Pharmacol Rev. 2020 Jul;72(3):606-638

Any other comments

Patient {{ $iPatientNo }}

Inclusion criteria:

DEMOGRAPHIC DATA

GENERAL EXAMINATION FINDINGS

DETAILS OF DIAGNOSIS

Mention others if any

Other Class of Drug given along with above therapy#

Voltage-gated sodium channels

Voltage-gated calcium channels (T-type)

GABAA receptors

SV2A inhibitor

α2δ subunit of calcium channels

AMPA receptor

Carbonic anhydratase inhibition

Mention others if any

#Molecular targets of clinically used ASDs

Other Class of Drug given along with above therapy^#

^#Molecular targets of clinically used ASDs